[Hypertension and chronic renal insufficiency].
In the last ten years the incidence of patients with terminal renal insufficiency has been continuously rising. A decrease in numbers is expected through vigorous treatment of systolic and diastolic blood pressure. Any antihypertensive therapy--independent of the substance group used--decreasing blood pressure, will slow down the progression of renal insufficiency. Whenever possible, an angiotensin-converting enzyme inhibitor should be part of the treatment, since these drugs have been shown to be renoprotective beyond their antihypertensive effect in certain renal diseases. This review will discuss pathogenesis, treatment and the use of renoprotective drugs in hypertensive patients with chronic renal failure.
Rosenkranz
A R
AR
Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Leopold-Franzens-Universität, Anichstrasse 35, A-6020 Innsbruck. alexander.rosenkranz@uibk.ac.at
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000503:physiopathology* / Q000517:prevention & control
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents